Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg iitos 600x60px
Document › Details

Medigene AG. (11/4/16). "Press Release: Medigene Participates at Six National and International Conferences". Martinsried.

Region Region Germany
Organisations Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
  Organisation 2 European Organization for Research and Treatment of Cancer (EORTC AISBL / IVWZ)
Products Product BIO-Europe 2016 Köln (Cologne)
  Product 2 TCR engineering technology (T-cell receptor engineering technology)
Person Person Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München)

Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at six upcoming scientific, investor and business development conferences:


Date: 7 - 9 November 2016
Location: Cologne, Germany

SITC 2016 - Society for Immunotherapy of Cancer

Date: 9 - 13 November 2016
Location: National Harbor, Maryland, USA

Neoantigens Summit

Date: 15 - 17 November 2016
Location: Boston, USA
Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will give a talk on the topic: "Are we Limited to Treatment of Tumors with High-Mutational Loads and Patients with Pre-Existing Neoantigen-Specific T Cells?"

6th Munich Biomarker Conference

Date: 29 - 30 November 2016
Location: Munich, Germany
Prof. Dr. Dolores Schendel, Medigene's CEO/CSO, will give a keynote talk on the topic: "From personalized to individualized medicine, the next major step in developing the medicine of the future".

EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

Date: 29 November - 2 December 2016
Location: Munich, Germany

ASH 2016 - The 58th American Society of Hematology Annual Meeting

Date: 3 - 6 December 2016
Location: San Diego, USA

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,

In case you no longer wish to receive any information about Medigene, please inform us by e-mail ( We will then delete your address from our distribution list.

Record changed: 2017-07-02


Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg iito 600x60px

More documents for Medigene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top